Government-Owned Inventions; Availability for Licensing, 32713-32714 [2017-14861]
Download as PDF
asabaliauskas on DSKBBXCHB2PROD with NOTICES
Federal Register / Vol. 82, No. 135 / Monday, July 17, 2017 / Notices
The prospective exclusive license
territory may be worldwide and the
field of use may be limited to the use
of Licensed Patent Rights for the
following: ‘‘Development, commercial
application and use of fulvestrant in
estrogen receptor positive cancers, in
combination with other products and
therapies, excluding poxvirus-based
vaccines.’’ For avoidance of doubt, the
field of use specifically excludes the use
of fulvestrant in combination with
poxvirus-based vaccines.
This technology discloses the use of
fulvestrant, an estrogen receptor
antagonist, as an immune modulating
agent that enhances the effects of
immunotherapy and/or chemotherapy
in cancer cells. Fulvestrant treatment of
mesenchymal-like lung carcinoma cells
increases immune-mediated lysis by
reversing epithelial mesenchymal
transition (EMT), potentially repairing
defective cell death mechanisms driven
by EMT, and restoring immunemediated lysis to chemo-resistant cells.
Overall, treatment of cancer cells with
fulvestrant in combination with
immunotherapy or chemotherapy agents
results in increased cancer cell death.
Although immunotherapy is leading the
charge in cancer treatments, its efficacy
is limited by patient resistance to
immunotherapy and/or nonresponsiveness. Combination therapy
with fulvestrant that enhances the
therapeutic effects of immunotherapy
and chemotherapy, is a promising
strategy to improve the clinical outcome
for patients with resistant or
unresponsive tumors.
This notice is made in accordance
with 35 U.S.C. 209 and 37 CFR part 404.
The prospective exclusive license will
be royalty bearing, and the prospective
exclusive license may be granted unless
within fifteen (15) days from the date of
this published notice, the National
Cancer Institute receives written
evidence and argument that establishes
that the grant of the license would not
be consistent with the requirements of
35 U.S.C. 209 and 37 CFR part 404.
Complete applications for a license in
the prospective field of use that are filed
in response to this notice will be treated
as objections to the grant of the
contemplated Exclusive
Commercialization Patent License
Agreement. Comments and objections
submitted to this notice will not be
made available for public inspection
and, to the extent permitted by law, will
not be released under the Freedom of
Information Act, 5 U.S.C. 552.
VerDate Sep<11>2014
17:45 Jul 14, 2017
Jkt 241001
Dated: July 6, 2017.
Richard U. Rodriguez,
Associate Director, Technology Transfer
Center, National Cancer Institute.
[FR Doc. 2017–14860 Filed 7–14–17; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institute on Drug Abuse;
Amended Notice of Meeting
Notice is hereby given of a change in
the meeting of the National Institute on
Drug Abuse Special Emphasis Panel,
July 27, 2017, 09:00 a.m. to July 27,
2017, 05:00 p.m., National Institutes of
Health, Neuroscience Center, 6001
Executive Boulevard, Rockville, MD
20852 which was published in the
Federal Register on June 29, 2017, 82
125 FR 2017–13696.
This meeting was amended to change
the date from July 27, 2017 to July 25,
2017. The time of the meeting remains
the same. The meeting is closed to the
public.
Dated: July 10, 2017.
Natasha M. Copeland,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2017–14858 Filed 7–14–17; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions;
Availability for Licensing
National Institutes of Health,
HHS.
ACTION:
Notice.
The invention listed below is
owned by an agency of the U.S.
Government and is available for
licensing to achieve expeditious
commercialization of results of
federally-funded research and
development. Foreign patent
applications are filed on selected
inventions to extend market coverage
for companies and may also be available
for licensing.
FOR FURTHER INFORMATION CONTACT: Dr.
Peter Tung; 240–669–5483; peter.tung@
nih.gov. Licensing information and
copies of the patent applications listed
below may be obtained by
communicating with the indicated
licensing contact at the Technology
Transfer and Intellectual Property
SUMMARY:
PO 00000
Frm 00038
Fmt 4703
Sfmt 4703
Office, National Institute of Allergy and
Infectious Diseases, 5601 Fishers Lane,
Rockville, MD, 20852; tel. 301–496–
2644. A signed Confidential Disclosure
Agreement will be required to receive
copies of unpublished patent
applications.
SUPPLEMENTARY INFORMATION:
Technology description follows.
Compounds That Treat Malaria and
Prevent Malaria Transmission
National Institutes of Health
AGENCY:
32713
Description of Technology
Malaria is the single leading cause of
death, especially among children, in the
developing world. Malaria is caused by
infection with parasites of the genus
Plasmodium, transmitted by mosquitos.
In addition to transmission, vital steps
in the parasite lifecycle occur in the
mosquito host. The invention offered for
licensing relates to therapeutic
compounds and related pharmaceutical
compositions that can be used in the
prevention and treatment of malaria
infection. More specifically, the
invention is drawn to compounds that
may kill sexual and mosquito stage
malaria parasites to block transmission.
Specifically claimed is the
antihistamine Ketotifen, which has
demonstrated activity blocking parasite
development in mosquitoes. Also
claimed are treatments encompassing
Ketotifen with other existing
antimalarial drugs in a combination
treatment aimed at multiple stages in
the malaria life cycle.
This technology is available for
licensing for commercial development
in accordance with 35 U.S.C. 209 and 37
CFR part 404, as well as for further
development and evaluation under a
research collaboration.
Potential Commercial Applications
• Prevention and treatment of malaria
infections
Competitive Advantages
• Drugs that kill sexual and mosquito
stages of the parasite are important for
preventing and/or slowing the spread of
malaria infection and ultimately for
malaria eradication.
• Primaquine, the only currently
available drug shown to block
transmission, is known to cause serious
adverse side effects.
Development Stage
• Pre-Clinical (animal data available)
Inventors: Xin-zhuan Su and Dipak
Raj (NIAID).
Publications: Eastman R.T.
Pattaradilokrat S. Raj D.K. Dixit S. Deng
B. Miura K. Yuan J. Tanaka T.Q.
Johnson R.L. Jiang H. et al. 2013. A class
E:\FR\FM\17JYN1.SGM
17JYN1
32714
Federal Register / Vol. 82, No. 135 / Monday, July 17, 2017 / Notices
of tricyclic compounds blocking malaria
parasite oocyst development and
transmission. Antimicrob. Agents
Chemother. 57: 425–435.
Intellectual Property: US Patent #
9,375,424, US divisional patent
application: 13/392,668, Worldwide
patent applications: Canada 2772085,
Europe 10812670.7, India 1684/DELNP/
2012. Priority Application 61/237,417
filed August 27, 2009. (HHS Reference
No. E–283–2009)
Licensing Contact: Peter Tung, Ph.D.;
240–669–5483; peter.tung@nih.gov.
Collaborative Research Opportunity:
The National Institute of Allergy and
Infectious Diseases is seeking statements
of capability or interest from parties
interested in collaborative research to
further develop, evaluate or
commercialize this technology. For
collaboration opportunities, please
contact Peter Tung; 240–669–5483;
peter.tung@nih.gov.
Dated: July 6, 2017.
Suzanne Frisbie,
Deputy Director, Technology Transfer and
Intellectual Property Office, National Institute
of Allergy and Infectious Diseases.
[FR Doc. 2017–14861 Filed 7–14–17; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
asabaliauskas on DSKBBXCHB2PROD with NOTICES
National Institute of Allergy and
Infectious Diseases; Notice of Closed
Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Microbiology,
Infectious Diseases and AIDS Initial Review
Group; Acquired Immunodeficiency
Syndrome Research Review Committee
AIDS.
Date: August 10–11, 2017.
Time: 8:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
VerDate Sep<11>2014
17:45 Jul 14, 2017
Jkt 241001
Place: National Institutes of Health, 5601
Fishers Lane, Rockville, MD 20892
(Telephone Conference Call).
Contact Person: Robert C. Unfer, Ph.D.,
Scientific Review Officer, Scientific Review
Program, Division of Extramural Activities,
Room 3F40A, National Institutes of Health,
NIAID, 5601 Fishers Lane, MSC 9834,
Bethesda, MD 20892–9834, (240) 669–5035,
robert.unfer@nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.855, Allergy, Immunology,
and Transplantation Research; 93.856,
Microbiology and Infectious Diseases
Research, National Institutes of Health, HHS)
Dated: July 10, 2017.
Natasha M. Copeland,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2017–14856 Filed 7–14–17; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Allergy and
Infectious Diseases; Notice of Closed
Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Allergy and Infectious Diseases Special
Emphasis Panel; NIAID Clinical Trial
Planning Grant (R34).
Date: August 8, 2017.
Time: 1:15 p.m. to 2:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 5601
Fishers Lane, Rockville, MD 20892
(Telephone Conference Call).
Contact Person: Louis A. Rosenthal, Ph.D.,
Scientific Review Officer, Immunology
Review Branch, 5601 Fishers Lane,
Telephone: 240–669–5070, Fax: 301–480–
2408, rosenthalla@niaid.nih.gov.
Name of Committee: National Institute of
Allergy and Infectious Diseases Special
Emphasis Panel; NIAID Clinical Trial
Planning Grant (R34).
Date: August 8, 2017.
Time: 12:00 p.m. to 1:15 p.m.
PO 00000
Frm 00039
Fmt 4703
Sfmt 4703
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 5601
Fishers Lane, Rockville, MD 20892
(Telephone Conference Call).
Contact Person: Louis A. Rosenthal, Ph.D.,
Scientific Review Officer, Immunology
Review Branch, 5601 Fishers Lane,
Telephone: 240–669–5070, Fax: 301–480–
2408, rosenthalla@niaid.nih.gov.
Name of Committee: National Institute of
Allergy and Infectious Diseases Special
Emphasis Panel; NIAID Clinical Trial
Implementation Grant (R01).
Date: August 10, 2017.
Time: 1:00 p.m. to 2:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 5601
Fishers Lane, Rockville, MD 20892
(Telephone Conference Call).
Contact Person: Roberta Binder, Ph.D.,
Scientific Review Officer, Scientific Review
Program, Division of Extramural Activities,
Room 3G21A, National Institutes of Health/
NIAID, 5601 Fishers Lane, MSC 9823,
Bethesda, MD 20892–9823, (240) 669–5050,
rbinder@niaid.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.855, Allergy, Immunology,
and Transplantation Research; 93.856,
Microbiology and Infectious Diseases
Research, National Institutes of Health, HHS)
Dated: July 10, 2017.
Natasha M. Copeland,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2017–14855 Filed 7–14–17; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Center for Scientific Review; Notice of
Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Member
Conflict: International and Cooperative
Projects 1.
Date: July 21, 2017.
Time: 10:30 a.m. to 12:00 p.m.
E:\FR\FM\17JYN1.SGM
17JYN1
Agencies
[Federal Register Volume 82, Number 135 (Monday, July 17, 2017)]
[Notices]
[Pages 32713-32714]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2017-14861]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions; Availability for Licensing
AGENCY: National Institutes of Health, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The invention listed below is owned by an agency of the U.S.
Government and is available for licensing to achieve expeditious
commercialization of results of federally-funded research and
development. Foreign patent applications are filed on selected
inventions to extend market coverage for companies and may also be
available for licensing.
FOR FURTHER INFORMATION CONTACT: Dr. Peter Tung; 240-669-5483;
peter.tung@nih.gov. Licensing information and copies of the patent
applications listed below may be obtained by communicating with the
indicated licensing contact at the Technology Transfer and Intellectual
Property Office, National Institute of Allergy and Infectious Diseases,
5601 Fishers Lane, Rockville, MD, 20852; tel. 301-496-2644. A signed
Confidential Disclosure Agreement will be required to receive copies of
unpublished patent applications.
SUPPLEMENTARY INFORMATION: Technology description follows.
Compounds That Treat Malaria and Prevent Malaria Transmission
Description of Technology
Malaria is the single leading cause of death, especially among
children, in the developing world. Malaria is caused by infection with
parasites of the genus Plasmodium, transmitted by mosquitos. In
addition to transmission, vital steps in the parasite lifecycle occur
in the mosquito host. The invention offered for licensing relates to
therapeutic compounds and related pharmaceutical compositions that can
be used in the prevention and treatment of malaria infection. More
specifically, the invention is drawn to compounds that may kill sexual
and mosquito stage malaria parasites to block transmission.
Specifically claimed is the antihistamine Ketotifen, which has
demonstrated activity blocking parasite development in mosquitoes. Also
claimed are treatments encompassing Ketotifen with other existing
antimalarial drugs in a combination treatment aimed at multiple stages
in the malaria life cycle.
This technology is available for licensing for commercial
development in accordance with 35 U.S.C. 209 and 37 CFR part 404, as
well as for further development and evaluation under a research
collaboration.
Potential Commercial Applications
Prevention and treatment of malaria infections
Competitive Advantages
Drugs that kill sexual and mosquito stages of the parasite
are important for preventing and/or slowing the spread of malaria
infection and ultimately for malaria eradication.
Primaquine, the only currently available drug shown to
block transmission, is known to cause serious adverse side effects.
Development Stage
Pre-Clinical (animal data available)
Inventors: Xin-zhuan Su and Dipak Raj (NIAID).
Publications: Eastman R.T. Pattaradilokrat S. Raj D.K. Dixit S.
Deng B. Miura K. Yuan J. Tanaka T.Q. Johnson R.L. Jiang H. et al. 2013.
A class
[[Page 32714]]
of tricyclic compounds blocking malaria parasite oocyst development and
transmission. Antimicrob. Agents Chemother. 57: 425-435.
Intellectual Property: US Patent # 9,375,424, US divisional patent
application: 13/392,668, Worldwide patent applications: Canada 2772085,
Europe 10812670.7, India 1684/DELNP/2012. Priority Application 61/
237,417 filed August 27, 2009. (HHS Reference No. E-283-2009)
Licensing Contact: Peter Tung, Ph.D.; 240-669-5483;
peter.tung@nih.gov.
Collaborative Research Opportunity: The National Institute of
Allergy and Infectious Diseases is seeking statements of capability or
interest from parties interested in collaborative research to further
develop, evaluate or commercialize this technology. For collaboration
opportunities, please contact Peter Tung; 240-669-5483;
peter.tung@nih.gov.
Dated: July 6, 2017.
Suzanne Frisbie,
Deputy Director, Technology Transfer and Intellectual Property Office,
National Institute of Allergy and Infectious Diseases.
[FR Doc. 2017-14861 Filed 7-14-17; 8:45 am]
BILLING CODE 4140-01-P